NV Tranexamic Acid
NV Tranexamic Acid contains tranexamic acid encapsulated in lipid particles with particle diameter larger than 200nm. The blend encapsulation through the Nanovetores Technology allows the stabilization of sensitive components, therefore, complex of being formulated in their free form, providing NV Tranexamic Acid a powerful whitening action, being recommended for the treatment of melasma and for the prevention of UV-induced skin pigmentation.
TRANEXAMIC ACID
Tranexamic acid (trans-4-(Aminomethyl) cyclohexane-carboxylic acid) works by inhibiting the conversion of plasminogen into plasmin, this substance is released when the skin suffers some type of aggression such as sun exposure and acne inflammation. Plasmin stimulates inflammatory factors which in turn increase the production of melanin, by inhibiting this substance, the production of melanin is automatically inhibited, providing a whitening effect on the skin.1 Plasminogen is responsible for the increased activity of melanocytes in vitro, and blocking this effect may be the paracrine mechanism for reducing melasma hyperpigmentation. Thus, tranexamic acid has been studied as an effective alternative for the treatment of melasma.
Melasma is an acquired chronic hypermelanosis characterized by brownish macules on exposed areas of the skin, especially on the frontal and malar regions. It affects both sexes, with a higher incidence in women, especially pregnant women. It occurs in all races. particularly in individuals with high skin phototypes, who live in areas with high rates of ultraviolet (UV) radiation. UV radiation is an important factor involved in the peroxidation of lipids in the cell membrane, with the release of free radicals, which would stimulate melanocytes. There are many factors involved in the etiology of the disease: genetic influences, exposure to UV radiation, pregnancy, hormonal therapies, cosmetics, sun sensitizing drugs, endocrinopathies, stress, among others.